Oxford Biomedica (OXB) RNS Announcements

Add to Alert list
Date Time Source Announcement
24 Sep 2018 12:20 PM
RNS
Director/PDMR Shareholding
20 Sep 2018 10:55 AM
EQS
Oxford BioMedica (OXB): Partnering strategy del...
13 Sep 2018 07:00 AM
RNS
Oxford BioMedica Interim Results
13 Sep 2018 07:00 AM
RNS
Oxford BioMedica further capacity expansion
03 Sep 2018 09:18 AM
RNS
Total Voting Rights
28 Aug 2018 07:00 AM
RNS
Kymriah® receives European Commission Approval
22 Aug 2018 11:58 AM
RNS
Director/PDMR Shareholding
15 Aug 2018 07:00 AM
RNS
RNS notice of results OXB
14 Aug 2018 07:15 AM
EQS
Oxford BioMedica (OXB): Risk-sharing in cystic ...
13 Aug 2018 10:55 AM
RNS
Director/PDMR Shareholding
13 Aug 2018 10:48 AM
RNS
Director/PDMR Shareholding
10 Aug 2018 11:39 AM
RNS
PDMR Dealings / Market Share Sale
10 Aug 2018 11:36 AM
RNS
Director Dealings / Market Share Sale and Purchase
08 Aug 2018 02:45 PM
RNS
Share Options and LTIPs Granted
06 Aug 2018 07:02 AM
RNS
Partnership for Cystic Fibrosis Gene Therapy
01 Aug 2018 09:53 AM
RNS
Total Voting Rights
23 Jul 2018 12:54 PM
RNS
Director Dealings / Market Share Purchase
02 Jul 2018 10:25 AM
RNS
Directorate Change
02 Jul 2018 09:47 AM
RNS
Total Voting Rights
29 Jun 2018 01:37 PM
RNS
Kymriah receives positive CHMP opinion
25 Jun 2018 05:19 PM
RNS
Holdings in Company
22 Jun 2018 12:05 PM
RNS
Confirmation of change of Auditor
22 Jun 2018 12:03 PM
RNS
Director Dealings / Market Share Purchase
21 Jun 2018 05:52 PM
RNS
Holdings in Company
14 Jun 2018 09:50 AM
EQS
Oxford BioMedica (OXB): Gene-therapy for Parkin...
06 Jun 2018 07:00 AM
RNS
OXB and Axovant Sciences Licence Agreement
04 Jun 2018 06:08 PM
RNS
Directorate Change
01 Jun 2018 09:24 AM
RNS
Block Listing Return
01 Jun 2018 09:19 AM
RNS
Total Voting Rights
30 May 2018 04:23 PM
RNS
Holdings in Company
29 May 2018 01:21 PM
RNS
Result of General Meeting
29 May 2018 01:21 PM
RNS
Result of AGM
23 May 2018 01:40 PM
RNS
Director Dealings / Market Share Purchase
04 May 2018 07:00 AM
RNS
Proposed Share Capital Consolidation
02 May 2018 07:00 AM
RNS
Kymriah receives FDA approval for DLBCL
01 May 2018 09:37 AM
RNS
Total Voting Rights
26 Apr 2018 03:33 PM
RNS
Holding(s) in Company
26 Apr 2018 07:30 AM
RNS
2017 Annual Report and Accounts & AGM Notification
23 Apr 2018 11:46 AM
RNS
Director Dealings / Market Share Purchase
11 Apr 2018 02:11 PM
RNS
Director Dealings / Market Share Purchase
09 Apr 2018 05:39 PM
RNS
Director/PDMR Shareholding
09 Apr 2018 10:47 AM
RNS
Director/PDMR Shareholding
05 Apr 2018 12:08 PM
RNS
Director/PDMR Shareholding
03 Apr 2018 09:45 AM
RNS
Total Voting Rights
22 Mar 2018 11:05 AM
RNS
Director/PDMR Shareholding
20 Mar 2018 07:15 AM
RNS
Hardman & Co Res: Supply to meet demand
15 Mar 2018 07:01 AM
RNS
Board Change
15 Mar 2018 07:01 AM
RNS
Preliminary Results
09 Mar 2018 06:41 PM
RNS
Result of Placing
09 Mar 2018 03:42 PM
RNS
PROPOSED PLACING TO RAISE APPROXIMATELY £20.5M

Oxford Biomedica is a company that specialises in cell and gene therapy, and is a leader in the development of gene-based medicines. They work with pharmaceutical and biotechnology companies to develop and manufacture viral vectors, including lentivirus, adeno-associated virus, and adenoviral vectors.

Headquartered in Oxford, Oxford Biomedica has manufacturing facilities in Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US.

Oxford Biomedica share price listed in London under the ticker OXB at 2,570p.

UK 100